Compare Stocks: SRZN, WVE, DSGN, and DBVT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DBVT DBV Technologies	$11.55 -5.1%	$13.64	$8.85 ▼ $26.18	$725.64M	-0.95	300,023 shs	174,780 shs
DSGN Design Therapeutics	$11.99 -3.0%	$13.82	$5.28 ▼ $17.25	$748.48M	1.66	602,686 shs	148,884 shs
SRZN Surrozen	$31.89 +97.3%	$21.48	$11.39 ▼ $35.86	$371.01M	0.56	191,841 shs	8.65 million shs
WVE WAVE Life Sciences	$3.86 -2.4%	$5.22	$3.83 ▼ $21.73	$755.69M	-1.3	3.77 million shs	813,949 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DBVT DBV Technologies	-3.64%	+3.22%	-13.93%	-24.03%	+30.16%
DSGN Design Therapeutics	-6.08%	-1.20%	-18.84%	-8.04%	+105.32%
SRZN Surrozen	-8.18%	-4.55%	-32.58%	-34.09%	+33.77%
WVE WAVE Life Sciences	-9.20%	-12.42%	-22.85%	-31.30%	-42.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DBVT DBV Technologies	$11.55 -5.1%	$13.64	$8.85 ▼ $26.18	$725.64M	-0.95	300,023 shs	174,780 shs
DSGN Design Therapeutics	$11.99 -3.0%	$13.82	$5.28 ▼ $17.25	$748.48M	1.66	602,686 shs	148,884 shs
SRZN Surrozen	$31.89 +97.3%	$21.48	$11.39 ▼ $35.86	$371.01M	0.56	191,841 shs	8.65 million shs
WVE WAVE Life Sciences	$3.86 -2.4%	$5.22	$3.83 ▼ $21.73	$755.69M	-1.3	3.77 million shs	813,949 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DBVT DBV Technologies	-3.64%	+3.22%	-13.93%	-24.03%	+30.16%
DSGN Design Therapeutics	-6.08%	-1.20%	-18.84%	-8.04%	+105.32%
SRZN Surrozen	-8.18%	-4.55%	-32.58%	-34.09%	+33.77%
WVE WAVE Life Sciences	-9.20%	-12.42%	-22.85%	-31.30%	-42.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DBVT DBV Technologies	2.57	Moderate Buy	$48.50	319.77% Upside
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	37.61% Upside
SRZN Surrozen	2.71	Moderate Buy	$45.00	41.13% Upside
WVE WAVE Life Sciences	2.76	Moderate Buy	$22.31	478.79% Upside

Current Analyst Ratings Breakdown

Latest SRZN, WVE, DSGN, and DBVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	WVE WAVE Life Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight ➝ Neutral
9/10/2026	DBVT DBV Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/20/2026	SRZN Surrozen	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$51.00
8/20/2026	SRZN Surrozen	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$51.00
8/19/2026	WVE WAVE Life Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/10/2026	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$44.00
8/4/2026	WVE WAVE Life Sciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$27.00 ➝ $23.00
8/3/2026	WVE WAVE Life Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$13.00
8/3/2026	WVE WAVE Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/31/2026	WVE WAVE Life Sciences	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$31.00 ➝ $22.00
7/31/2026	WVE WAVE Life Sciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$24.00 ➝ $19.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DBVT DBV Technologies	$5.64M	128.81	N/A	N/A	$4.20 per share	2.75
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.73 per share	N/A
SRZN Surrozen	$11.51M	32.16	N/A	N/A	($19.21) per share	-1.66
WVE WAVE Life Sciences	$42.73M	17.78	N/A	N/A	$3.10 per share	1.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
SRZN Surrozen	-$242.03M	-$40.55	N/A	N/A	N/A	-2,885.33%	N/A	-93.62%	11/6/2026 (Estimated)
WVE WAVE Life Sciences	-$204.38M	-$1.09	N/A	N/A	N/A	-309.73%	-50.36%	-40.06%	11/9/2026 (Estimated)

Latest SRZN, WVE, DSGN, and DBVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	SRZN Surrozen	-$1.29	-$0.41	+$0.88	-$0.41	$0.47 million	$5.00 million
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A
7/30/2026	Q2 2026	WVE WAVE Life Sciences	-$0.2998	-$0.34	-$0.0403	-$0.34	$7.45 million	$2.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DBVT DBV Technologies	N/A	3.72	3.72
DSGN Design Therapeutics	N/A	18.86	18.86
SRZN Surrozen	N/A	12.14	12.14
WVE WAVE Life Sciences	N/A	9.99	9.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DBVT DBV Technologies	71.74%
DSGN Design Therapeutics	56.64%
SRZN Surrozen	66.57%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
DBVT DBV Technologies	1.06%
DSGN Design Therapeutics	17.10%
SRZN Surrozen	31.74%
WVE WAVE Life Sciences	24.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DBVT DBV Technologies	161	62.88 million	62.21 million	Optionable
DSGN Design Therapeutics	55	62.58 million	51.88 million	Optionable
SRZN Surrozen	44	11.61 million	7.93 million	Not Optionable
WVE WAVE Life Sciences	317	197.05 million	149.17 million	Optionable

SRZN, WVE, DSGN, and DBVT Headlines

Recent News About These Companies

Reviewing WAVE Life Sciences (NASDAQ:WVE) & Protalix BioTherapeutics (NYSE:PLX)

September 24 at 5:16 AM | americanbankingnews.com

Wave Life Sciences Initiates Phase 2a Trial of Obesity Drug WVE-007 in Combination With Tirzepatide

September 23 at 8:53 PM | finance.yahoo.com

Wave Life Sciences avvia trial di fase 2a per l’obesità con WVE-007

September 23 at 8:53 PM | it.investing.com

WAVE Life Sciences (NASDAQ:WVE) Trading Down 6.6% - Here's Why

September 23 at 12:19 PM | marketbeat.com

JPMorgan Chase & Co. Reiterates "Neutral" Rating for WAVE Life Sciences (NASDAQ:WVE)

September 23 at 8:23 AM | marketbeat.com

Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity

September 23 at 7:30 AM | globenewswire.com

Wave Life Sciences Names Monika Vnuk Chief Business Officer

September 22 at 6:48 PM | rttnews.com

Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer

September 22 at 7:30 AM | globenewswire.com

Comparing WAVE Life Sciences (NASDAQ:WVE) and Septerna (NASDAQ:SEPN)

September 22 at 6:15 AM | americanbankingnews.com

WAVE Life Sciences (NASDAQ:WVE) Hits New 52-Week Low - What's Next?

September 22 at 4:41 AM | americanbankingnews.com

WAVE Life Sciences (NASDAQ:WVE) Sets New 12-Month Low - Time to Sell?

September 22 at 4:39 AM | marketbeat.com

Head to Head Survey: Regeneron Pharmaceuticals (NASDAQ:REGN) and WAVE Life Sciences (NASDAQ:WVE)

September 20, 2026 | americanbankingnews.com

WAVE Life Sciences (NASDAQ:WVE) Reaches New 52-Week Low - What's Next?

September 16, 2026 | americanbankingnews.com

WAVE Life Sciences (NASDAQ:WVE) Hits New 1-Year Low - Should You Sell?

September 16, 2026 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Hits New 12-Month Low - Here's What Happened

September 10, 2026 | marketbeat.com

WAVE Life Sciences Ltd. $WVE Stock Holdings Boosted by Squarepoint Ops LLC

September 10, 2026 | marketbeat.com

Readystate Asset Management LP Purchases New Shares in WAVE Life Sciences Ltd. $WVE

September 7, 2026 | marketbeat.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Moderate Buy" from Analysts

September 4, 2026 | marketbeat.com

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

September 3, 2026 | globenewswire.com

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 4.3% - Time to Sell?

September 2, 2026 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Reaches New 12-Month Low - What's Next?

August 31, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN, WVE, DSGN, and DBVT Company Descriptions

DBV Technologies NASDAQ:DBVT

$11.55 -0.62 (-5.06%)

As of 11:45 AM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Design Therapeutics NASDAQ:DSGN

$11.99 -0.37 (-2.99%)

As of 11:46 AM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Surrozen NASDAQ:SRZN

$31.88 +15.73 (+97.31%)

As of 11:46 AM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

WAVE Life Sciences NASDAQ:WVE

$3.86 -0.10 (-2.41%)

As of 11:46 AM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRZN, WVE, DSGN, and DBVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRZN, WVE, DSGN, and DBVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRZN, WVE, DSGN, and DBVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN, WVE, DSGN, and DBVT Company Descriptions

DBV Technologies NASDAQ:DBVT

Design Therapeutics NASDAQ:DSGN

Surrozen NASDAQ:SRZN

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRZN, WVE, DSGN, and DBVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRZN, WVE, DSGN, and DBVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRZN, WVE, DSGN, and DBVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN, WVE, DSGN, and DBVT Company Descriptions

DBV Technologies NASDAQ:DBVT

Design Therapeutics NASDAQ:DSGN

Surrozen NASDAQ:SRZN

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools